Hanmi Pharmaceutical Co was founded by Lim Sung-Gi in 1973 and is headquartered in Hwaseong-si, South Korea.
The engages in the manufacture and sale of pharmaceutical products. Its products include medicines for high blood pressure, hyperlipidemia, reflux esophagitis, and cerebrovascular disease.
In 2014, Hanmi invested over 150 billion won in R&D for the first time. Based on this, Hanmi focuses on developing new drug projects such as LAPSCOVERY and anticancer drugs targeting the global market.
Hanmi has globally proven its high technology and capacity with FDC (fixed-dose combinations) drugs. Amosartan, a hypertension drug, is exported to 51 countries around the world through Merck. Hanmi also develops and proceeds with many FDC drug projects with GSK.